Matthew Wilson
Last active: 12/13/2018

Profile

My expertise is in caring for patients with chronic kidney disease.  I am particularly interested in patients with genetic forms of kidney disease, undiscovered genetic forms of kidney disease, and developing new therapies for kidney disease and its complications.

My translational research efforts are focused on engineering new therapeutic approaches which are lacking in preventing progression of kidney disease or dealing with its complications.  Currently, my research focuses on developing a novel cell therapy for anemia which is a common issue for patients with kidney disease, especially end-stage kidney disease.  My efforts are also directed towards developing gene-based approaches for correcting gene defects or preventing progression of kidney disease. My research laboratory is funded both by the NIH and VA. 

Publications

The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. CRISPR/Cas9 engineering of a KIM-1 reporter human proximal tubule cell line. Veach RA, Wilson MH (2018) PLoS One 13(9): e0204487
    › Primary publication · 30260998 (PubMed) · PMC6160069 (PubMed Central)
  2. Integration Mapping of piggyBac-Mediated CD19 Chimeric Antigen Receptor T Cells Analyzed by Novel Tagmentation-Assisted PCR. Hamada M, Nishio N, Okuno Y, Suzuki S, Kawashima N, Muramatsu H, Tsubota S, Wilson MH, Morita D, Kataoka S, Ichikawa D, Murakami N, Taniguchi R, Suzuki K, Kojima D, Sekiya Y, Nishikawa E, Narita A, Hama A, Kojima S, Nakazawa Y, Takahashi Y (2018) EBioMedicine : 18-26
    › Primary publication · 30082227 (PubMed) · PMC6116345 (PubMed Central)
  3. Consider Changing the Horse for Your CAR-T? Wilson MH (2018) Mol Ther 26(8): 1873-1874
    › Primary publication · 30078438 (PubMed) · PMC6094485 (PubMed Central)
  4. Enhanced Expression of Anti-CD19 Chimeric Antigen Receptor in Transposon-Engineered T Cells. Morita D, Nishio N, Saito S, Tanaka M, Kawashima N, Okuno Y, Suzuki S, Matsuda K, Maeda Y, Wilson MH, Dotti G, Rooney CM, Takahashi Y, Nakazawa Y (2018) Mol Ther Methods Clin Dev : 131-140
    › Primary publication · 29687032 (PubMed) · PMC5907825 (PubMed Central)
  5. Transposon-modified antigen-specific T lymphocytes for sustained therapeutic protein delivery in vivo. O'Neil RT, Saha S, Veach RA, Welch RC, Woodard LE, Rooney CM, Wilson MH (2018) Nat Commun 9(1): 1325
    › Primary publication · 29636469 (PubMed) · PMC5893599 (PubMed Central)
  6. Hydrodynamic Renal Pelvis Injection for Non-viral Expression of Proteins in the Kidney. Woodard LE, Welch RC, Williams FM, Luo W, Cheng J, Wilson MH (2018) J Vis Exp (131)
    › Primary publication · 29364221 (PubMed) · PMC5907682 (PubMed Central)
  7. Comparative analysis of chimeric ZFP-, TALE- and Cas9-piggyBac transposases for integration into a single locus in human cells. Luo W, Galvan DL, Woodard LE, Dorset D, Levy S, Wilson MH (2017) Nucleic Acids Res 45(14): 8411-8422
    › Primary publication · 28666380 (PubMed) · PMC5737283 (PubMed Central)
  8. Kidney-specific transposon-mediated gene transfer in vivo. Woodard LE, Cheng J, Welch RC, Williams FM, Luo W, Gewin LS, Wilson MH (2017) Sci Rep : 44904
    › Primary publication · 28317878 (PubMed) · PMC5357952 (PubMed Central)
  9. Temporal self-regulation of transposition through host-independent transposase rodlet formation. Woodard LE, Downes LM, Lee YC, Kaja A, Terefe ES, Wilson MH (2017) Nucleic Acids Res 45(1): 353-366
    › Primary publication · 27899587 (PubMed) · PMC5224482 (PubMed Central)
  10. Anti-proliferative effects of T cells expressing a ligand-based chimeric antigen receptor against CD116 on CD34(+) cells of juvenile myelomonocytic leukemia. Nakazawa Y, Matsuda K, Kurata T, Sueki A, Tanaka M, Sakashita K, Imai C, Wilson MH, Koike K (2016) J Hematol Oncol : 27
    › Primary publication · 26983639 (PubMed) · PMC4793548 (PubMed Central)
  11. Neurosarcoidosis Presenting as Aseptic Meningitis in an Immunosuppressed Renal Transplant Recipient. Held EP, Iglesia EA, Johnson AS, Fang JY, Wilson MH, Abel TW, Lake W, Siew ED (2016) Transplantation 100(10): e96-e100
    › Primary publication · 26863472 (PubMed)
  12. Anti-Tumor Effects after Adoptive Transfer of IL-12 Transposon-Modified Murine Splenocytes in the OT-I-Melanoma Mouse Model. Galvan DL, O'Neil RT, Foster AE, Huye L, Bear A, Rooney CM, Wilson MH (2015) PLoS One 10(10): e0140744
    › Primary publication · 26473608 (PubMed) · PMC4608718 (PubMed Central)
  13. piggyBac-ing models and new therapeutic strategies. Woodard LE, Wilson MH (2015) Trends Biotechnol 33(9): 525-33
    › Primary publication · 26211958 (PubMed) · PMC4663986 (PubMed Central)
  14. Protective role of insulin-like growth factor-1 receptor in endothelial cells against unilateral ureteral obstruction-induced renal fibrosis. Liang M, Woodard LE, Liang A, Luo J, Wilson MH, Mitch WE, Cheng J (2015) Am J Pathol 185(5): 1234-50
    › Primary publication · 25783760 (PubMed) · PMC4419212 (PubMed Central)
  15. Evaluating the potential for undesired genomic effects of the piggyBac transposon system in human cells. Saha S, Woodard LE, Charron EM, Welch RC, Rooney CM, Wilson MH (2015) Nucleic Acids Res 43(3): 1770-82
    › Primary publication · 25605795 (PubMed) · PMC4330379 (PubMed Central)
  16. Anti-leukemic potency of piggyBac-mediated CD19-specific T cells against refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. Saito S, Nakazawa Y, Sueki A, Matsuda K, Tanaka M, Yanagisawa R, Maeda Y, Sato Y, Okabe S, Inukai T, Sugita K, Wilson MH, Rooney CM, Koike K (2014) Cytotherapy 16(9): 1257-69
    › Primary publication · 25108652 (PubMed) · PMC4948190 (PubMed Central)
  17. Targeting piggyBac transposon integrations in the human genome. Galvan DL, Kettlun CS, Wilson MH (2014) Methods Mol Biol : 143-61
    › Primary publication · 24557901 (PubMed)
  18. An adaptable system for improving transposon-based gene expression in vivo via transient transgene repression. Doherty JE, Woodard LE, Bear AS, Foster AE, Wilson MH (2013) FASEB J 27(9): 3753-62
    › Primary publication · 23752206 (PubMed) · PMC3752539 (PubMed Central)
  19. Evaluation of long-term transgene expression in piggyBac-modified human T lymphocytes. Nakazawa Y, Saha S, Galvan DL, Huye L, Rollins L, Rooney CM, Wilson MH (2013) J Immunother 36(1): 3-10
    › Primary publication · 23211626 (PubMed) · PMC3521868 (PubMed Central)
  20. Comparative analysis of the recently discovered hAT transposon TcBuster in human cells. Woodard LE, Li X, Malani N, Kaja A, Hice RH, Atkinson PW, Bushman FD, Craig NL, Wilson MH (2012) PLoS One 7(11): e42666
    › Primary publication · 23166581 (PubMed) · PMC3499496 (PubMed Central)
  21. piggyBac transposon system modification of primary human T cells. Saha S, Nakazawa Y, Huye LE, Doherty JE, Galvan DL, Rooney CM, Wilson MH (2012) J Vis Exp (69): e4235
    › Primary publication · 23149543 (PubMed) · PMC3514050 (PubMed Central)
  22. Hyperactive piggyBac gene transfer in human cells and in vivo. Doherty JE, Huye LE, Yusa K, Zhou L, Craig NL, Wilson MH (2012) Hum Gene Ther 23(3): 311-20
    › Primary publication · 21992617 (PubMed) · PMC3300075 (PubMed Central)
  23. Combining mTor inhibitors with rapamycin-resistant T cells: a two-pronged approach to tumor elimination. Huye LE, Nakazawa Y, Patel MP, Yvon E, Sun J, Savoldo B, Wilson MH, Dotti G, Rooney CM (2011) Mol Ther 19(12): 2239-48
    › Primary publication · 21878902 (PubMed) · PMC3242659 (PubMed Central)
  24. PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor. Nakazawa Y, Huye LE, Salsman VS, Leen AM, Ahmed N, Rollins L, Dotti G, Gottschalk SM, Wilson MH, Rooney CM (2011) Mol Ther 19(12): 2133-43
    › Primary publication · 21772253 (PubMed) · PMC3242651 (PubMed Central)
  25. Manipulating piggyBac transposon chromosomal integration site selection in human cells. Kettlun C, Galvan DL, George AL, Kaja A, Wilson MH (2011) Mol Ther 19(9): 1636-44
    › Primary publication · 21730970 (PubMed) · PMC3182353 (PubMed Central)
  26. Designing and testing chimeric zinc finger transposases. Wilson MH, George AL (2010) Methods Mol Biol : 353-63
    › Primary publication · 20680846 (PubMed)
  27. Tamoxifen-inducible podocyte-specific iCre recombinase transgenic mouse provides a simple approach for modulation of podocytes in vivo. Wang J, Wang Y, Long J, Chang BH, Wilson MH, Overbeek P, Danesh FR (2010) Genesis 48(7): 446-51
    › Primary publication · 20641128 (PubMed) · PMC3014324 (PubMed Central)
  28. Multiplexed transposon-mediated stable gene transfer in human cells. Kahlig KM, Saridey SK, Kaja A, Daniels MA, George AL, Wilson MH (2010) Proc Natl Acad Sci U S A 107(4): 1343-8
    › Primary publication · 20080581 (PubMed) · PMC2824351 (PubMed Central)
  29. piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies. Manuri PV, Wilson MH, Maiti SN, Mi T, Singh H, Olivares S, Dawson MJ, Huls H, Lee DA, Rao PH, Kaminski JM, Nakazawa Y, Gottschalk S, Kebriaei P, Shpall EJ, Champlin RE, Cooper LJ (2010) Hum Gene Ther 21(4): 427-37
    › Primary publication · 19905893 (PubMed) · PMC2938363 (PubMed Central)
  30. PiggyBac transposon-based inducible gene expression in vivo after somatic cell gene transfer. Saridey SK, Liu L, Doherty JE, Kaja A, Galvan DL, Fletcher BS, Wilson MH (2009) Mol Ther 17(12): 2115-20
    › Primary publication · 19809403 (PubMed) · PMC2814386 (PubMed Central)
  31. Optimization of the PiggyBac transposon system for the sustained genetic modification of human T lymphocytes. Nakazawa Y, Huye LE, Dotti G, Foster AE, Vera JF, Manuri PR, June CH, Rooney CM, Wilson MH (2009) J Immunother 32(8): 826-36
    › Primary publication · 19752751 (PubMed) · PMC2796278 (PubMed Central)
  32. Genome-wide mapping of PiggyBac transposon integrations in primary human T cells. Galvan DL, Nakazawa Y, Kaja A, Kettlun C, Cooper LJ, Rooney CM, Wilson MH (2009) J Immunother 32(8): 837-44
    › Primary publication · 19752750 (PubMed) · PMC2796288 (PubMed Central)
  33. PiggyBac transposon-mediated gene transfer in human cells. Wilson MH, Coates CJ, George AL (2007) Mol Ther 15(1): 139-45
    › Primary publication · 17164785 (PubMed)
  34. Functional zinc finger/sleeping beauty transposase chimeras exhibit attenuated overproduction inhibition. Wilson MH, Kaminski JM, George AL (2005) FEBS Lett 579(27): 6205-9
    › Primary publication · 16243318 (PubMed)
  35. Heterozygous alpha 2A-adrenergic receptor mice unveil unique therapeutic benefits of partial agonists. Tan CM, Wilson MH, MacMillan LB, Kobilka BK, Limbird LE (2002) Proc Natl Acad Sci U S A 99(19): 12471-6
    › Primary publication · 12205290 (PubMed) · PMC129469 (PubMed Central)
  36. The role of a conserved inter-transmembrane domain interface in regulating alpha(2a)-adrenergic receptor conformational stability and cell-surface turnover. Wilson MH, Highfield HA, Limbird LE (2001) Mol Pharmacol 59(4): 929-38
    › Primary publication · 11259639 (PubMed)
  37. Mechanisms regulating the cell surface residence time of the alpha 2A-adrenergic receptor. Wilson MH, Limbird LE (2000) Biochemistry 39(4): 693-700
    › Primary publication · 10651634 (PubMed)
  38. Evaluation of the alpha(2A)-adrenergic receptor gene in a heritable form of temporal lobe epilepsy. Wilson MH, Puranam RS, Ottman R, Gilliam C, Limbird LE, George AL, McNamara JO (1998) Neurology 51(6): 1730-1
    › Primary publication · 9855534 (PubMed)